Long-term cost-consequence analysis of exenatide once weekly vs sitagliptin or pioglitazone for the treatment of type 2 diabetes patients in the United States

Journal of Medical Economics

Volumn 15, Issue 4, 2012, Pages 654-663

  Guillermin, Anne Laure ^a   Lloyd, Adam ^a   Best, Jennie H ^b   Deyoung, Mary Beth ^b   Samyshkin, Yevgeniy ^a   Gaebler, Julia Aledort ^b  

^a IQVIA   (United States)

^b AMYLIN PHARMACEUTICALS INC   (United States)

Author keywords

Costs; Exenatide; Modeling; Pioglitazone; Sitagliptin; Type 2 diabetes; United States

Indexed keywords

EXENDIN 4; HEMOGLOBIN A1C; PIOGLITAZONE; SITAGLIPTIN;

ACUTE HEART INFARCTION; ADULT; AMPUTATION; ANGINA PECTORIS; BODY MASS; BODY WEIGHT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CATARACT; CONGESTIVE HEART FAILURE; COST BENEFIT ANALYSIS; COST CONTROL; DIABETIC FOOT; DIABETIC MACULAR EDEMA; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DISEASE DURATION; DRUG COST; FEMALE; HEALTH CARE COST; HUMAN; HYPOGLYCEMIA; INJECTION SITE REACTION; KIDNEY FAILURE; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PERIPHERAL VASCULAR DISEASE; PROTEINURIA; QUALITY OF LIFE; REVIEW; STROKE; UNITED STATES; VISUAL IMPAIRMENT;

ADULT; COHORT STUDIES; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; LONG-TERM CARE; MALE; MARKOV CHAINS; MIDDLE AGED; MODELS, THEORETICAL; PEPTIDES; PYRAZINES; THIAZOLIDINEDIONES; TRIAZOLES; UNITED STATES; VENOMS;

EID: 84862508854     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2012.670677     Document Type: Review

References (34)

1. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009;15:540-59
2. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2009;32:193-203
3. VanDeKoppel S, Choe HM, Sweet BV. Managed care perspective on three new agents for type 2 diabetes. J Manag Care Pharm 2008;14:363-80 (Pubitemid 351890851)
4. Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999;281:2005-12 (Pubitemid 29254858)
5. Aronoff SL, Berkowitz K, Shreiner B, et al. Glucose metabolism and regulation: beyond insulin and glucagon. Diabetes Spectrum 2004;17:183-90
6. BYETTA-(exenatide) Injection [prescribing information]. San Diego, CA: Amlyin Pharmaceuticals, Inc., 2011
7. Deyoung MB, MacConell L, Sarin V, et al. Encapsulation of exenatide in Poly-(d,l-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes. Diabetes Technol Ther 2011;13:1145-54
8. Fineman M, Flanagan S, Taylor K, et al. Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosing. Clin Pharmacokinet 2011;50:65-74
9. Bergenstal RM, Wysham C, MacConell L, et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 2010;376:431-9
10. Palmer AJ, Roze S, Valentine WJ, et al. The CORE Diabetes Model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin 2004;20(1 Suppl):S5-26
11. Palmer AJ, Roze S, Valentine WJ, et al. Validation of the CORE Diabetes Model against epidemiological and clinical studies. Curr Med Res Opin 2004;20(1 Suppl):S27-40 (Pubitemid 39349906)
12. Computer modeling of diabetes and its complications: a report on the Fourth Mount Hood Challenge Meeting. Diabetes Care 2007;30:1638-46
13. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of longterm complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86
14. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53
15. Guidelines for computer modeling of diabetes and its complications. Diabetes Care 2004;27:2262-5
16. Woodroffe R, Yao GL, Meads C, et al. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study. Health Technol Assess 2005;9:1-179, iii-iv
17. Wasserfallen JB, Halabi G, Saudan P, et al. Quality of life on chronic dialysis: comparison between haemodialysis and peritoneal dialysis. Nephrol Dial Transplant 2004;19:1594-9 (Pubitemid 38786756)
18. Tengs TO, Wallace A. One thousand health-related quality-of-life estimates. Med Care 2000;38:583-637
19. Sharma S, Oliver-Fernandez A, Bakal J, et al. Utilities associated with diabetic retinopathy: results from a Canadian sample. Br J Opthamol 2003;87:259-61 (Pubitemid 36307893)
20. Redekop WK, Stolk EA, Kok E, et al. Diabetic foot ulcers and amputations: estimates of health utility for use in cost-effectiveness analyses of new treatments. Diabetes Metab 2004;30:549-56 (Pubitemid 40070357)
21. Lloyd A, Nafees B, Gavriel S, et al. Health utility values associated with diabetic retinopathy. Diabet Med 2008;25:618-24 (Pubitemid 351590891)
22. Hopkins RB, Tarride JE, Bowen J, et al. Cost-effectiveness of reducing wait times for cataract surgery in Ontario. Can J Ophthalmol 2008;43:213-7 (Pubitemid 351518174)
23. Clarke P, Gray A, Holman R. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making 2002;22:340-9 (Pubitemid 34791321)
24. Currie CJ, Morgan CL, Poole CD, et al. Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes. Curr Med Res Opin 2006;22:1523-34 (Pubitemid 44297431)
25. Bagust A, Beale S. Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data. Health Econ 2005;14:217-30 (Pubitemid 40360759)
26. Matza LS, Boye KS, Yurgin N, et al. Utilities and disutilities for type 2 diabetes treatment-related attributes. Qual Life Res 2007;16:1251-65 (Pubitemid 47357727)
27. Boye KS, Matza LS, Walter KN, et al. Utilities and disutilities for attributes of injectable treatments for type 2 diabetes. Eur J Health Econ 2011;12:219-30
28. PriceRx Medispan Wholesale Acquisition Costs (WAC). 2010. http://www.medi-span.com/index.aspx. Accessed January 1, 2010
29. Consumer Price Index for Medical Care Services. US Department of Labor, Bureau of Labor Statistics. 2006. http://www.bls.gov/cpi. Accessed July 1, 2010
30. U.K. Prospective Diabetes Study Group. U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995;44:1249-58
31. Beaudet A, Wilson B, Caputo J, et al. Projected long-term clinical and economic outcomes of exenatide once weekly versus sitagliptin for the treatment of type 2 diabetes in the UK [abstract]. Value Heath 2011;14:A476
32. Kiberd BA, Jindal KK. Screening to prevent renal failure in insulin dependent diabetic patients: an economic evaluation. BMJ 1995;311:1595-9 (Pubitemid 26002703)
33. Pelletier EM, Smith PJ, Boye KS, et al. Direct medical costs for type 2 diabetes mellitus complications in the US commercial payer setting: a resource for economic research. Appl Health Econ Health Policy 2008;6:103-12
34. O'Brien JA, Patrick AR, Caro J. Estimates of direct medical costs for microvascular and macrovascular complications resulting from type 2 diabetes mellitus in the United States in 2000. Clin Ther 2003; 25:1017-38 (Pubitemid 36459706)